+25.9%
GSK vs VIK
+225.3%
-199.4%
-28.5%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 3y.
| Period | Portfolio | VIK | Excess | Alpha |
|---|---|---|---|---|
| 1D | +0.2% | -3.4% | +3.6% | +0.4% |
| 7D | -3.6% | -0.8% | -2.8% | -3.5% |
| 30D | -5.9% | -18.0% | +12.1% | -4.5% |
| 3M | -4.3% | -5.8% | +1.5% | -4.0% |
| 6M | -10.8% | +17.2% | -28.0% | -12.1% |
| YTD | +1.8% | +19.1% | -17.3% | +0.2% |
| 1Y | +23.5% | +33.6% | -10.2% | +21.2% |
| All | +25.9% | +225.3% | -199.4% | +23.9% |
Cumulative growth
Daily Returns
Daily percentage return beside VIK.
Daily Out/Under-Performance
Portfolio return minus VIK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × VIK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 3y: compounded portfolio wealth divided by compounded VIK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
3y analysis · Full analysis span regression · 6 months rolling